Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR5311)
Drug Name
Carfilzomib
Synonyms
Carfilzomib; 868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide
Indication Multiple myeloma [ICD11: 2A83] Approved [1]
Lung cancer [ICD11: ICD11: 2C25] Phase 1/2 [2]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 719.9 Topological Polar Surface Area 159
Heavy Atom Count 52 Rotatable Bond Count 20
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 8
Cross-matching ID
PubChem CID
11556711
ChEBI ID
CHEBI:65347
CAS Number
868540-17-4
TTD Drug ID
D00UVA
Formula
C40H57N5O7
Canonical SMILES
CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4
InChI
InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1
InChIKey
BLMPQMFVWMYDKT-NZTKNTHTSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Carfilzomib metabolite M14 DM016548
121299208
Hydrolysis - Peptide hydrolysis 1 [3]
Carfilzomib metabolite M15 DM016513
118673135
Hydrolysis - Peptide hydrolysis 1 [3]
Carfilzomib metabolite M16 DM016603
134356203
Hydrolysis - Hydrolysis 1 [3]
Carfilzomib metabolite M14 DM016548
121299208
Unclear - Unclear 2 [4]
Carfilzomib metabolite M14 DM016548
121299208
Unclear - Unclear 2 [3]
Carfilzomib metabolite M15 DM016513
118673135
Unclear - Unclear 2 [3]
Carfilzomib metabolite M14 DM016548
121299208
Unclear - Unclear 3 [4]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR007826 Carfilzomib Carfilzomib metabolite M16 Hydrolysis - Hydrolysis EPHX1 [3]
MR007830 Carfilzomib Carfilzomib metabolite M15 Hydrolysis - Peptide hydrolysis Unclear [3]
MR007831 Carfilzomib Carfilzomib metabolite M14 Hydrolysis - Peptide hydrolysis CTSA [3]
MR007827 Carfilzomib metabolite M16 Carfilzomib metabolite M15 Unclear - Unclear CTSA [3]
MR007829 Carfilzomib metabolite M16 Carfilzomib metabolite M14 Unclear - Unclear CTSA [3]
MR007828 Carfilzomib metabolite M15 Carfilzomib metabolite M14 Unclear - Unclear Unclear [4]
⏷ Show the Full List of 6 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Epoxide hydrolase 1 (EPHX1) DME0623 Homo sapiens
HYEP_HUMAN
3.3.2.9
[3]
peptidases (PPD) DMEN809 Homo sapiens Not Available Not Available [3]
References
1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7420).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism Int J Mol Sci. 2021 Oct 27;22(21):11595. doi: 10.3390/ijms222111595.
4 Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.